A2A ADENOSINE AGONIST ADJUNCT FOR SYSTEMIC ANTHRAX

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 1R41AI053042-01
Agency Tracking Number: AI053042
Amount: $198,360.00
Phase: Phase I
Program: STTR
Awards Year: 2002
Solicitation Year: N/A
Solicitation Topic Code: N/A
Solicitation Number: N/A
Small Business Information
ADENOSINE THERAPEUTICS, LLC
ADENOSINE THERAPEUTICS, LLC, 300 PRESTON AVE, 5TH FL, CHARLOTTESVILLE, VA, 22902
DUNS: N/A
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 W SCHELD
 (434) 924-5241
 WMS@VIRGINIA.EDU
Business Contact
 ROBERT CAPON
Phone: (434) 220-9400
Email: RSCAPON@AOL.COM
Research Institution
 UNIVERSITY OF VIRGINIA
 UVA
CHARLOTTESVILLE, VA, 24615
 Nonprofit college or university
Abstract
DESCRIPTION (provided by applicant): This project develops A2A adenosine receptor (A2AAR) agonists as adjuncts to antibiotics for the treatment of anthrax septicemia. It responds to the urgent need for better treatment of highly lethal infections by this bioterrorism/biowarfare agent. Phase I has two aims, pharmaceutical development and documentation of efficacy in clinically relevant settings. The goal of Aim I is to identify one lead and two to three backup compounds for development. It applies USP criteria to the screening of the company library of 50 proprietary A2AAR agonists for pharmaceutically relevant factors such as in vitro efficacy, solubility, stability to heat, light and pH, followed by secondary screens to document physical characteristics such as pKa, hydrophobicity and affinity for plasma proteins. The goal of Aim 2 is to demonstrate preliminary efficacy. It develops a mouse model of anthrax toxin sepsis by: (1) dose-ranging studies on anthrax lethal toxin (LT); (2) dose-ranging studies of A2AAR agonist protection against LT sepsis; (3) studies of the effect of delay in administration of A2AAR agonist on protection against LT sepsis, and (4) documentation that the A2AAR specifically mediates the protective effect of these agonists. Attaining both aims will argue for continuing on to Phase II for additional assessments of efficacy as well as of pharmacokinetics and metabolism.

* information listed above is at the time of submission.

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government